Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by ImCheck Therapeutics SAS

ImCheck to Present Updated ICT01 Data with Unprecedented High Rates of Complete Remission in AML at the AACR Annual Meeting 2025
From ImCheck Therapeutics SAS
Via GlobeNewswire
ImCheck to Present Encouraging Interim Results in AML Patients from the EVICTION Trial at the 66th American Society of Hematology Annual Meeting
From ImCheck Therapeutics SAS
Via GlobeNewswire
ImCheck to Present Updated Data from the EVICTION Trial at the 39th Annual Meeting of the Society for Immunotherapy of Cancer
From ImCheck Therapeutics SAS
Via GlobeNewswire
ImCheck Receives FDA Fast Track Designation for ICT01 in Combination with Azacitidine and Venetoclax in First-Line Acute Myeloid Leukemia for Patients Unfit for Induction Chemotherapy Treatment
From ImCheck Therapeutics SAS
Via GlobeNewswire
ImCheck Awarded EUR 20.18 Million from the French Government Through the France 2030 Investment and Innovation Plan
From ImCheck Therapeutics SAS
Via GlobeNewswire
ImCheck Appoints Stephan Braun as Chief Medical Officer
From ImCheck Therapeutics SAS
Via GlobeNewswire
ImCheck to Present Promising ICT01 Data from the EVICTION Study at ASCO 2024
From ImCheck Therapeutics SAS
Via GlobeNewswire
ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023
From ImCheck Therapeutics SAS
Via GlobeNewswire
ImCheck To Present EVICTION-2 Data on ICT01 Combination With Low Dose IL-2 In Patients with Advanced Solid Tumors at SITC Annual Meeting
From ImCheck Therapeutics SAS
Via GlobeNewswire
Correction: ImCheck to Present New Positive Data on ICT01 Monotherapy in Hematological Cancers at ESMO 2023
From ImCheck Therapeutics SAS
Via GlobeNewswire
ImCheck to Present New Positive Data on ICT01 Monotherapy in Hematological Cancers at ESMO 2023
From ImCheck Therapeutics SAS
Via GlobeNewswire
ImCheck Achieves the Primary Objectives of Phase I of the EVICTION-2 Trial of ICT01 in Combination with Low Dose IL-2, Data Presented at AACR 2023
From ImCheck Therapeutics SAS
Via GlobeNewswire
ImCheck Appoints Thomas Civik as Independent Chairman of the Board
From ImCheck Therapeutics SAS
Via GlobeNewswire
ImCheck To Present Data From the EVICTION-2 Study of ICT01 in Combination With IL-2 In Patients with Advanced Solid Tumors at AACR
From ImCheck Therapeutics SAS
Via GlobeNewswire
ImCheck Presents Initial Patient Data from the EVICTION-2 Clinical Trial at SITC Annual Meeting
From ImCheck Therapeutics SAS
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.